Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

S A Schey, P Fields, J B Bartlett, I A Clarke, G Ashan, R D Knight, M Streetly, A G Dalgleish

    Research output: Contribution to journalArticle

    280 Citations (Scopus)

    Abstract

    To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.
    Original languageEnglish
    Pages (from-to)3269-76
    Number of pages8
    JournalJournal of Clinical Oncology
    Volume22
    Issue number16
    DOIs
    Publication statusPublished - 2004

    Fingerprint Dive into the research topics of 'Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004). Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 22(16), 3269-76. https://doi.org/10.1200/JCO.2004.10.052